Akèy › Ensifizyans kadyak › Tennessee › Nashville
Etid klinik pou Ensifizyans kadyak nan Nashville, TN
19 etid pou Ensifizyans kadyak ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
ELEVATE-HFpEF Clinical Study
Ap rekrite
- Saint Thomas Research Institute, Nashville
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Ap rekriteFaz 3
- Research Site, Nashville
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Ap rekriteFaz 2
- Vanderbilt University Medical Center, Nashville
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Ap rekriteFaz 3
- Vanderbilt University Medical Center, Nashville
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Ap rekriteFaz 3
- Research Site, Nashville
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Ap rekriteFaz 3
- Nashville, TN Investigative Site 10071, Nashville
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Ap rekrite
- St.Thomas Health, Nashville
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
Ap rekriteEtid obsèvasyon
- Vanderbilt University, Nashville
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Ap rekriteEtid obsèvasyon
- Nashville, Nashville
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Ap rekriteEtid obsèvasyon
- Tristar Centennial Medical Ctr, Nashville
- Saint Thomas Health, Nashville
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Ap rekriteFaz 3
- Tenax Investigational Site, Nashville
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
Ap rekriteEtid obsèvasyon
- Vanderbilt University, Nashville
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Ap rekrite
- Vanderbilt, Nashville
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt University Medical Center, Nashville
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Ap rekrite
- Centennial Medical Center, Nashville
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
Ap rekrite
- Vanderbilt University Medical Center, Nashville
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
Ap rekriteEtid obsèvasyon
- Vanderbilt University Medical Center, Nashville
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
Ap rekriteEtid obsèvasyon
- Vanderbilt University Medical Center, Nashville
Etid Ensifizyans kadyak nan lòt vil
- New York City, NY51 etid
- Boston, MA44 etid
- Dallas, TX42 etid
- Houston, TX36 etid
- Cleveland, OH33 etid
- Chicago, IL31 etid
- Philadelphia, PA31 etid
- San Francisco, CA29 etid
- St. Louis, MO26 etid
- Durham, NC26 etid
- Atlanta, GA25 etid
- Kansas City, MO25 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete80 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat42 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.